The estimated Net Worth of Ronald Peck is at least $3.67 Milione dollars as of 23 February 2024. Mr. Peck owns over 1,699 units of Arvinas Inc stock worth over $1,680,473 and over the last 5 years he sold ARVN stock worth over $79,938. In addition, he makes $1,914,550 as Chief Medical Officer at Arvinas Inc.
Sign up
Mr. Peck ARVN stock SEC Form 4 insiders trading
Ronald has made over 8 trades of the Arvinas Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 1,699 units of ARVN stock worth $79,938 on 23 February 2024.
The largest trade he's ever made was exercising 20,000 units of Arvinas Inc stock on 30 December 2021 worth over $830,600. On average, Ronald trades about 5,980 units every 99 days since 2019. As of 23 February 2024 he still owns at least 67,516 units of Arvinas Inc stock.
You can see the complete history of Mr. Peck stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Ronald Peck biography
Ronald Peck M.D. serves as Chief Medical Officer of the Company. Prior joining Arvinas, Dr. Peck served as Senior Vice President, Clinical Research at Tesaro, Inc., a biopharmaceutical company, from April 2017 to July 2019. He was also Chief Medical Officer of Koltan Pharmaceuticals, Inc., a biopharmaceutical company, from August 2015 to December 2016. Dr. Peck served as Vice President, Yervoy Global Development Lead at Bristol Myers Squibb, a biopharmaceutical company, from December 2011 to May 2015. Dr. Peck holds an M.D. from Thomas Jefferson University Medical College and a B.S. in chemistry from Georgetown University.
What is the salary of Ronald Peck?
As the Chief Medical Officer of Arvinas Inc, the total compensation of Ronald Peck at Arvinas Inc is $1,914,550. There are 3 executives at Arvinas Inc getting paid more, with John Houston having the highest compensation of $5,485,840.
How old is Ronald Peck?
Ronald Peck is 54, he's been the Chief Medical Officer of Arvinas Inc since 2019. There are 11 older and 6 younger executives at Arvinas Inc. The oldest executive at Arvinas Inc is Laurie Smaldone Alsup, 66, who is the Independent Director.
What's Ronald Peck's mailing address?
Ronald's mailing address filed with the SEC is C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVENUE, NEW HAVEN, CT, 06511.
Insiders trading at Arvinas Inc
Over the last 6 years, insiders at Arvinas Inc have traded over $123,187,141 worth of Arvinas Inc stock and bought 3,567,290 units worth $69,124,444 . The most active insiders traders include Capital Management, L.P.Ra ..., Liam Ratcliffe e Kush Parmar. On average, Arvinas Inc executives and independent directors trade stock every 22 days with the average trade being worth of $1,884,820. The most recent stock trade was executed by John G Houston on 23 February 2024, trading 5,196 units of ARVN stock currently worth $244,472.
What does Arvinas Inc do?
arvinas is a pharmaceutical company focused on developing new small molecules ‒ known as protacs (proteolysis targeting chimeras) ‒ aimed at degrading disease-causing cellular proteins via proteolysis. based on innovative research conducted at yale university by dr. craig crews, founder and chief scientific advisor, the company is translating natural protein degradation approaches into novel drugs for the treatment of cancer and other diseases. the proprietary protac-based drug paradigm induces protein degradation, rather than protein inhibition, using the ubiquitin proteasome system and offers the advantage of potentially targeting “undruggable” as well as “druggable” elements of the proteome. this greatly expands the ability to create drugs for many new, previously unapproachable targets. for more information, visit www.arvinas.com.
What does Arvinas Inc's logo look like?
Complete history of Mr. Peck stock trades at Arvinas Inc
Arvinas Inc executives and stock owners
Arvinas Inc executives and other stock owners filed with the SEC include:
-
John Houston,
President, Chief Executive Officer, Director -
Sean Cassidy,
Chief Financial Officer -
Ian Taylor,
Chief Scientific Officer -
Ronald Peck,
Chief Medical Officer -
Dr. John G. Houston Ph.D.,
CEO, Pres & Director -
Dr. Ronald A. Peck,
Chief Medical Officer -
Dr. Ian Taylor Ph.D.,
Chief Scientific Officer -
Sean A. Cassidy CPA, M.B.A., CPA,
CFO & Treasurer -
Laurie Smaldone Alsup,
Independent Director -
Leslie Norwalk,
Independent Director -
Timothy Shannon,
Independent Chairman of the Board -
Bradley Margus,
Independent Director -
Briggs Morrison,
Independent Director -
Liam Ratcliffe,
Independent Director -
Edward Kennedy,
Independent Director -
Wendy Dixon,
Director -
Linda Bain,
Director -
Steve Weiss,
VP of HR -
Dr. Randy Teel Ph.D.,
Sr. VP of Corp. & Bus. Devel. -
Dr. Robert Kleinfield,
Chief Devel. Officer -
Matthew Batters J.D.,
Gen. Counsel -
Jeff Boyle,
VP of Investor Relations -
Dr. Craig M. Crews,
Founder, Chief Scientific Advisor & Member of Scientific Advisory Board -
Ventures Iii, L.P.5 Am Part...,
-
David K Loomis,
Chief Accounting Officer -
Sunil Agarwal,
Director -
Ix L.P.Canaan Partners Ix L...,
-
Capital Management, L.P.Ra ...,
-
Jakob Loven,
Director -
Andrew Crew,
See Remarks -
Ventures Iii, L.P.5 Am Co I...,
-
James E Deerfield Mgmt L.P....,
-
Craig Martin Crews,
10% owner -
Kush Parmar,
Director -
Angela M Cacace,
Chief Scientific Officer -
John D Young,
Director -
Everett Cunningham,
Director -
Noah Berkowitz,
Chief Medical Officer -
Randy Teel,
Int. Chief Financial Officer